Cancer Study Buoys These Small Biotechs

Core Viewpoint - Terns Pharmaceuticals experienced a significant share price increase of up to 50% following the announcement that cancer cell counts decreased by over 99% in nearly 75% of leukemia patients treated with its once-daily pill [1] Company Summary - Terns Pharmaceuticals' once-daily pill has shown promising results in treating leukemia, with a notable reduction in cancer cell counts [1] - The treatment has been effective in nearly three-fourths (approximately 75%) of the patients, indicating a strong potential for the company's product in the oncology market [1]